This report is the full list of what Edinburgh Worldwide Investment Trust owned on 30 April 2026. Roughly 64% is in shares of listed companies, 30% in private, unlisted firms, and 6% in cash. The largest single private holding is SpaceX at almost 19%, so even though the public stock portion looks diversified, the fund is actually quite concentrated. For ordinary investors, this shows how a professional growth fund places bets and accepts that a third of its money can be hard to sell quickly. Worth a read because it reveals real holdings rather than just investment slogans.
Edinburgh Worldwide Investment Trust plc published its holdings report as of April 30, 2026. The portfolio is primarily composed of growth-oriented listed companies, with listed equities accounting for 63.7% of total assets. The top five holdings include Alnylam Pharmaceuticals (4.2%), Aehr Test Sys
This chapter is the complete holdings list of Edinburgh Worldwide Investment Trust plc as of April 30, 2026. The core information is the asset allocation structure and portfolio concentration: listed equities account for 63.7%, private company investments 30.2%, and net current assets 6.1%.
This chapter is a pure data disclosure, with no manager commentary. Below, the composition of holdings is broken down by asset class.
The asset allocation shows a clear bifurcation: approximately two-thirds is placed in listed equities, nearly one-third in less liquid private company investments, and cash and net current assets account for just 6.1%.
| Asset class | Market value (GBP) | % of total assets |
|---|---|---|
| Listed equities | 576,608,434 | 63.7% |
| Private company investments (excluding fixed interest) | 273,503,373 | 30.2% |
| Warrants | 0 | 0.0% |
| Net current assets | 55,599,768 | 6.1% |
| Total assets | 905,711,575 | 100.0% |
The listed equity portfolio comprises 69 holdings; the top five total approximately 15.2%, a relatively diversified structure; the largest single holding, Alnylam Pharmaceuticals is 4.2%, and more than half of the holdings each account for less than 1%.
| Holding | % of assets |
|---|---|
| Alnylam Pharmaceuticals | 4.2% |
| Aehr Test Systems | 2.8% |
| ASPEED Technology | 2.6% |
| Twist Bioscience | 2.4% |
| Xometry | 2.2% |
| Axon Enterprise | 2.1% |
| American Superconductor Corp | 2.0% |
| AeroVironment | 1.8% |
| JFrog | 1.7% |
| Oxford Nanopore Technologies | 1.6% |
| Astera Labs | 1.6% |
| BillionToOne | 1.5% |
| IREN | 1.4% |
| Guardant Health | 1.4% |
| Zillow Group (Class C) | 1.4% |
| Ceres Power | 1.3% |
| Upstart Holdings | 1.3% |
| Harmonic Drive Systems | 1.2% |
| dLocal | 1.2% |
| Exail Technologies | 1.1% |
| MP Materials | 1.1% |
| Raspberry Pi | 1.1% |
| Remaining 48 holdings | Each ≤1.0%; approximately 30.9% in total |
The holdings span semiconductors, biotechnology, defense technology, software, and other fields; geographically, U.S.-listed names dominate, with additional holdings in Taiwan, Japan, the UK, Israel, Australia, and South Korea.
Semiconductors and hard tech: ASPEED Technology (2.6%), Astera Labs (1.6%), BESI (0.8%), Sensirion (0.2%), Silergy (0.8%), Shibaura Mechatronics (0.5%), Park Systems (0.9%), PDF Solutions (0.5%), Impinj (0.9%). Biotechnology and healthcare: Alnylam Pharmaceuticals (4.2%), Twist Bioscience (2.4%), BillionToOne (1.5%), Genmab (0.9%), Revolution Medicines (1.0%), Stoke Therapeutics (0.7%). Defense and aerospace: AeroVironment (1.8%), Axon Enterprise (2.1%), Kratos Defense & Security (0.8%). Software and internet: JFrog (1.7%), Xometry (2.2%), Amplitude (0.5%), Appian (0.6%), Doximity (0.6%), Rubrik (0.8%), Upstart Holdings (1.3%), Zillow Group (Class A 0.2% + Class C 1.4%). New energy and materials: American Superconductor (2.0%), Ceres Power (1.3%), MP Materials (1.1%), QuantumScape (0.4%).
The report also retains zero-value positions: China Lumena New Mats., Chinook Therapeutics CVR Line, New Horizon Health, Reaction Engines, and Relativity Space (the latter in the private investments section) — all with book values written down to zero, yet the positions remain, reflecting the fund's stance of retaining impaired positions.
Private company investments account for 30.2% of assets — the defining feature that distinguishes this fund from most listed growth funds. Within them, PsiQuantum's two preferred share rounds total 5.1%, making it the largest private holding; Echodyne accounts for 1.9%; and the two Astranis Space Technologies series total 1.1%.
| Holding | % of assets |
|---|---|
| PsiQuantum (Series C + Series D preferred) | 3.1% + 2.0% = 5.1% |
| Echodyne Corp. (Series C-1 preferred) | 1.9% |
| Astranis Space Technologies (Series C + Series C Prime) | 1.0% + 0.1% = 1.1% |
| Space Exploration Technologies Corp (Series N preferred) | 18.9% |
| Shine Tech (Series E-2 + Series C-5 preferred) | 0.7% + 0.7% = 1.4% |
| Epic Games | 0.5% |
| Lightning Labs (Series B preferred) | 0.6% |
| KSQ Therapeutics (Series C preferred) | 0.3% |
| DNA Script (Series C preferred) | 0.1% |
| Snyk (common shares + Series F preferred) | 0.1% + 0.3% = 0.4% |
| C4X Discovery Holdings | 0.1% (plus warrants, valued at zero) |
| Reaction Engines / Relativity Space | 0.0% (written down to zero) |
Note: The report lists an 18.9% holding in "Space Exploration Technologies Corp Series N Pref." but provides no market value breakdown (the amount is missing from that row), leaving this chapter's data incomplete. Private company investments total GBP 273,503,373, accounting for 30.2% of assets, of which roughly 60% comes from the single SpaceX position.
Net current assets of just 6.1% show the fund is operating nearly fully invested; with private company investments at close to one-third of assets, the liquidity buffer is limited — the overall portfolio is a growth allocation with high exposure and low liquidity.
Among listed equities, no single holding exceeds 5%, and the top five total approximately 15.2% — a relatively high degree of diversification. In the private segment, however, Space Exploration Technologies (SpaceX) alone accounts for 18.9%; combined with PsiQuantum's 5.1%, the two largest private holdings represent 24% of total assets — the portfolio's actual concentration is far higher than the listed equity surface figures suggest. The fund's total assets amount to approximately GBP 906 million.
The end of the report mentions that additional asset allocation information, such as derivatives exposure, is included in the monthly factsheet; this chapter does not elaborate.